Data Release #9 Now Including 7TM G Protein Pathway Data
Data Release 9 expands the EvE Bio dataset with 25 new human protein targets across 7TM receptors (GPCRs) and kinases — and for the first time, introduces G Protein pathway data to pair with our β-arrestin2 pathway data, opening up a new dimension of compound pharmacology. Below is a snapshot of what's new in this release. Be sure to follow this page or sign up for our email updates if you want to continue to hear about new releases. Let us know below what you want to see more of in future releases or any other enhancements to improve your ML workflows with our data!
15 New 7TM Receptors (GPCRs) — G Protein Activation Pathway
- Metabolic Disease & Incretin Signaling — GLP1R, GIPR, GCGR
- Migraine & Pain — CGRP Receptor (CALCRL), AM1, AM2
- Bone Metabolism & Osteoporosis — PTH1R, PTH2R
- Stress Response & Neuropsychiatry — CRHR1, CRHR2
- Neuropsychiatry — TAAR1
- Gastric & GI Function — HRH2, SCTR, VIPR1, VIPR2
10 New Protein Kinases
- Tau Biology & Neurodegeneration — MARK2, MARK4, NUAK1
- Hippo Pathway & Tumor Suppression — MST1 (STK4)
- MAPK & Stress Signaling — MAP4K5 (KHS1), MINK1
- Immune Signaling & Oncology — FYN, FGR, FES
- Cytoskeletal Dynamics & Cancer Metastasis — LIMK1
New — G Protein Pathway Data for 7TM Targets!
Introducing a New Signaling Dimension: G Protein Pathway Data
Data Release 9 marks the first time EvE Bio is sharing G Protein (Gs subunit) pathway data for 7TM targets, adding a new signaling dimension to our dataset alongside our established β-arrestin2 recruitment pathway data.
This initial release includes G Protein pathway data for a subset of our 7TM targets, with a small number of targets now featuring compound activity data across both pathways. We will continue to expand our G Protein pathway coverage to include additional targets — both new and previously released β-arrestin2 pathway targets — in future data releases.
Why this matters:
GPCRs activate multiple downstream signaling cascades, and the balance between G Protein and β-arrestin pathways can influence whether a compound produces therapeutic benefit, unwanted side effects, or both. This concept, known as biased agonism or functional selectivity, has become one of the most important principles in modern GPCR drug discovery.
By beginning to build out paired pathway data across our 7TM targets, EvE Bio is laying the groundwork for researchers to explore compound activity across both signaling arms, giving a more complete view of a compound’s pharmacology as our dual-pathway coverage grows.